Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Cash & Equivalents (2016 - 2025)

Corcept Therapeutics' Cash & Equivalents history spans 10 years, with the latest figure at $120.5 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 5.62% year-over-year to $120.5 million; the TTM value through Dec 2025 reached $120.5 million, down 5.62%, while the annual FY2025 figure was $120.5 million, 5.62% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $120.5 million at Corcept Therapeutics, down from $125.1 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $299.9 million in Q1 2023 and bottomed at $35.3 million in Q2 2022.
  • The 5-year median for Cash & Equivalents is $107.3 million (2023), against an average of $111.8 million.
  • The largest annual shift saw Cash & Equivalents plummeted 62.96% in 2022 before it skyrocketed 387.68% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $77.6 million in 2021, then fell by 14.54% to $66.3 million in 2022, then surged by 104.36% to $135.6 million in 2023, then fell by 5.82% to $127.7 million in 2024, then dropped by 5.62% to $120.5 million in 2025.
  • Per Business Quant, the three most recent readings for CORT's Cash & Equivalents are $120.5 million (Q4 2025), $125.1 million (Q3 2025), and $102.7 million (Q2 2025).